➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKesson
Harvard Business School
Boehringer Ingelheim
Moodys

Last Updated: June 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for BGB-A317


Email this page to a colleague

« Back to Dashboard

What is the drug development status for BGB-A317?

BGB-A317 is an investigational drug.

There have been 91 clinical trials for BGB-A317. The most recent clinical trial was a Phase 1 trial, which was initiated on April 25th 2018.

The most common disease conditions in clinical trials are Lymphoma, Carcinoma, and Neoplasms. The leading clinical trial sponsors are BeiGene, Hutchison Medipharma Limited, and BeiGene USA, Inc.

There are five US patents protecting this investigational drug and fifteen international patents.

Recent Clinical Trials for BGB-A317
TitleSponsorPhase
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial CancerFloor BackesEarly Phase 1
A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast CancerSichuan Provincial People's HospitalPhase 2
Tislelizumab Plus BGB-A1217 Versus Durvalumab When Co-administered With Concurrent Chemoradiotherapy (cCRT) in Lung CancerBeiGenePhase 3

See all BGB-A317 clinical trials

Clinical Trial Summary for BGB-A317

Top disease conditions for BGB-A317
Top clinical trial sponsors for BGB-A317

See all BGB-A317 clinical trials

US Patents for BGB-A317

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BGB-A317   Try Before You Buy Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment Bristol-Myers Squibb Company (Princeton, NJ) Celldex Therapeutics, Inc. (Hampton, NJ)   Try Before You Buy
BGB-A317   Try Before You Buy Combination therapy with an anti-axl antibody-drug conjugate ADC THERAPEUTICS SA (Epalinges, CH) MEDIMMUNE LIMTIED (Cambridge, GB)   Try Before You Buy
BGB-A317   Try Before You Buy Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment Bristol-Myers Squibb Company (Princeton, NJ) Celldex Therapeutics, Inc. (Hampton, NJ)   Try Before You Buy
BGB-A317   Try Before You Buy Anti-CD8 antibodies and uses thereof REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY)   Try Before You Buy
BGB-A317   Try Before You Buy Radiolabeled anti-LAG3 antibodies for immuno-PET imaging REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY)   Try Before You Buy
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BGB-A317

Drugname Country Document Number Estimated Expiration Related US Patent
BGB-A317 Australia AU2018219909 2037-02-10   Try Before You Buy
BGB-A317 Brazil BR112019016336 2037-02-10   Try Before You Buy
BGB-A317 Canada CA3053348 2037-02-10   Try Before You Buy
BGB-A317 Chile CL2019002264 2037-02-10   Try Before You Buy
BGB-A317 China CN110650974 2037-02-10   Try Before You Buy
BGB-A317 Colombia CO2019008675 2037-02-10   Try Before You Buy
BGB-A317 Eurasian Patent Organization EA201991673 2037-02-10   Try Before You Buy
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
McKesson
Baxter
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.